Immunohistochemical Model to Predict Risk for Coronary Artery Disease and Failure in Heart Transplant Patients

American Journal of Transplantation

Volumn 1, Issue 3, 2001, Pages 251-259

  Labarrere, Carlos A ^a   Nelson, David R ^c   Pitts, Douglas E ^b   Kirlin, Philip C ^b   Halbrook, Harold ^b  

^a METHODIST RESEARCH INSTITUTE   (United States)

^b Methodist Transplant Center   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Coronary disease; Immunohistochemistry; Microcirculation; Risk factors; Transplantation

Indexed keywords

ACTIN; FIBRIN; HLA DR ANTIGEN; MONOCLONAL ANTIBODY; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BIOPSY; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; HEART TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ACTINS; ADULT; ANTIBODIES, MONOCLONAL; BIOPSY; CARDIOMYOPATHY, DILATED; CORONARY DISEASE; FIBRIN; HEART TRANSPLANTATION; HLA-DR ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TISSUE PLASMINOGEN ACTIVATOR; TRANSPLANTATION, HOMOLOGOUS;

EID: 0035453052     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1600-6135.ajt10309.x     Document Type: Article

References (38)

1. St. Goar FG, Pinto FJ, Alderman EL et al. Intracoronary ultrasound in cardiac transplant recipients: in vivo evidence of 'angiographically silent' intimal thickening. Circulation 1992; 85: 979-987.
2. Bourge RC, Naftel DC, Costanzo-Nordin M et al. Pretransplantation risk factors for death after heart transplantation: a multi-institutional study. J Heart Lung Transplant 1993; 12: 549-562.
3. Gao SZ, Hunt SA, Schroeder JS, Alderman EL, Hill IR, Stinson EB. Early development of accelerated graft coronary artery disease: risk factors and course. J Am Coll Cardiol 1996; 28: 673-679.
4. Miller LW, Wolford TL, Donohue TJ, Drury JH. Cardiac allograft vasculopathy: new insights from intravascular ultrasound and coronary flow measurements. Transplant Rev 1995; 9: 77-96.
5. Johnson DE, Gao SZ, Schroeder JS, De Campli WM, Billingham ME. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant 1989; 8: 349-359.
6. Yeung AC, Davis SF, Hauptman PJ et al. Incidence and progression of transplant coronary artery disease over 1 year: results of a multicenter trial with use of intravascular ultrasound. J Heart Lung Transplant 1995; 14: S215-S220.
7. Labarrere CA, Pitts D, Halbrook H, Faulk WP. Tissue plasminogen activator, plasminogen activatory inhibitor-1 and fibrin as indexes of clinical course in cardiac allograft recipients: an immunocytochemical study. Circulation 1994; 89: 1599-1608.
8. Faulk WP, Labarrere CA, Pitts D, Halbrook H. Vascular lesions in biopsy specimens devoid of cellular infiltrates: qualitative and quantitative immunocytochemical studies of human cardiac allografts. J Heart Lung Transplant 1993; 12: 219-229.
9. Faulk WP, Labarrere CA. Fibrinolytic and anticoagulant control of hemostasis in human cardiac and renal allografts. Major Probl Pathol 1994; 30: 49-65.
10. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Vascular tissue plasminogen activator and the development of coronary artery disease in heart transplant recipients. N Engl J Med 1995; 333: 1111-1116.
11. Labarrere CA, Pitts D, Nelson DR, Faulk WP. Coronary artery disease in cardiac allografts: association with arteriolar endothelial HLA-DR and ICAM-1 antigens. Transplant Proc 1995; 27: 1939-1940.
12. Labarrere CA, Nelson DR, Faulk WP. Endothelial activation and development of coronary artery disease in transplanted human hearts. JAMA 1997; 278: 1169-1175.
13. Faulk WP, Labarrere CA, Nelson DR, Pitts D. Coronary artery disease in cardiac allografts: association with arterial antithrombin. Transplant Proc 1995; 27: 1944-1946.
14. Labarrere CA, Nelson DR, Faulk WP. Myocardial fibrin deposits in first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med 1998; 105: 207-213.
15. Billingham ME, Cary NRB, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587-593.
16. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirous infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989; 261: 3561-3566.
17. Costanzo MR, Naftel DC, Pritzker MR et al. Heart transplant coronary artery disease detected by coronary angiography, a multi-institutional study of preoperative donor and recipient risk factors. Cardiac Transplant Research Database. J Heart Lung Transplant 1998; 17: 744-753.
18. Labarrere CA, Faulk WP. Antigenic identification of cells in spiral artery trophoblastic invasion: validation of histological studies by triple-antibody immunocytochemistry. Am J Obstet Gynecol 1994; 171: 165-171.
19. Pober JS. Cytokine-mediated activation of vascular endothelium: physiology and pathology. Am J Pathol 1988; 133: 426-433.
20. Marboe CC. Cardiac transplant vasculopathy. Major Probl Pathol 1994; 30: 111-132.
21. Hosenpud JD, Shipley GD, Wagner CR. Cardiac allograft vasculopathy: current concepts, recent developments, and future directions. J Heart Lung Transplant 1992; 11: 9-23.
22. Rose EA, Pepino P, Barr ML et al. Relation of HLA antibodies and graft atherosclerosis in human cardiac allograft recipients. J Heart Lung Transplant 1992; 11: S120-S123.
23. McIntyre JA, Wagenknecht DR, Faulk WP. Antiphospholipid antibodies in heart transplant recipients. Clin Cardiol 1995; 18: 575-580.
24. Dunn MJ, Crisp SJ, Rose ML, Taylor PM, Yacoub MH. Antiendothelial antibodies and coronary artery disease after cardiac transplantation. Lancet 1992; 339: 1566-1570.
25. Crisp SJ, Dunn MJ, Rose ML, Barbir M, Yacoub MH. Antiendothelial antibodies after heart transplantation: the accelerating factor in transplant-associated coronary artery disease? J Heart Lung Transplant 1994; 13: 81-92.
26. Russell PS, Chase CM, Winn HJ, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. I. Time course and immunogenetic and immunopathological considerations. Am J Pathol 1994; 144: 260-274.
27. Russell PS, Chase CM, Winn JH, Colvin RB. Coronary atherosclerosis in transplanted mouse hearts. II. Importance of humoral immunity. J Immunol 1994; 152: 5135-5141.
28. Gaudin PB, Rayburn BK, Hutchins GM et al. Peritransplant injury to the myocardium associated with the development of accelerated arteriosclerosis in heart transplant recipients. Am J Surg Pathol 1994; 18: 338-346.
29. Day JD, Rayburn BK, Gaudin PB et al. Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant 1995; 14: S142-S149.
30. Yilmaz S, Paavonen T, Hayry P. Chronic rejection of rat renal allografts. II. The impact of prolonged ischemia time on transplant histology. Transplantation 1992; 53: 823-827.
31. Land W, Schneeberger H, Schleibner S et al. The beneficial effect of human recombinant superoxide dismutase on acute and chronic rejection events in recipients of cadaveric renal transplants. Transplantation 1994; 57: 211-217.
32. Najarian JS, Gillingham KJ, Sutherland DER, Reinsmoen NL, Payne WE, Matas AJ. The impact of the quality of initial graft function on cadaver kidney transplants. Transplantation 1994; 57: 812-816.
33. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation, etiology, management and long-term significance. J Urol 1996; 155: 1831-1840.
34. McLean AG, Hughes D, Welsh KI et al. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation. Transplantation 1997; 63: 374-380.
35. Isobe M, Yagita H, Okumura K, Ihara A. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 1992; 255: 1125-1127.
36. Haug CE, Colvin RB, Delmonico FL et al. A phase I trial of immunosuppression with anti-ICAM-1 (CD54) mAb in allograft recipients. Transplantation 1993; 55: 766-772.
37. Suzuki J, Isobe M, Yamazaki S, Horie S, Okubo Y, Sekiguchi M. Inhibition of accelerated coronary atherosclerosis with short-term blockade of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 in a heterotopic murine model of heart transplantation. J Heart Lung Transplant 1997; 16: 1141-1148.
38. Ostrovsky L, Woodman RC, Payne D, Teoh D, Kubes P. Antithrombin III prevents and rapidly reverses leukocyte recruitment in ischemia/ reperfusion. Circulation 1997; 96: 2302-2310.